2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1118

Role of the Chemokine Receptor CXCR3 in the Function of Regulatory B Cells in Patients with SLE
Abstract Number: 20

Role of the Epigenetic Regulator EZH2 in Proinflammatory Macrophage Polarization and Signaling in Rheumatoid Arthritis
Abstract Number: 1921

Role of TLRs in the Abnormal Secretion of CXCL-4 By Plasmacytoid Dendritic Cells of Patients with Systemic Sclerosis
Abstract Number: 1769

Role of Topical Administration of Peptidylarginine Deiminase Inhibitors in Murine Lupus
Abstract Number: 2819

Rorc Antagonism Inhibits IL-23-Dependent Aberrant Bone Formation in Vivo
Abstract Number: 591

Rosuvastatin Improves Endothelial Function in Patients with Inflammatory Joint Diseases, Longitudinal Associations with Atherosclerosis and Arteriosclerosis
Abstract Number: 1644

Routine Assessment of Patient Index Data 3 (RAPID3)-Defined Remission Is As Stringent As ACR/EULAR Boolean-Defined Remission in a Clinical Trial of Patients with Early Rheumatoid Arthritis Treated with Abatacept
Abstract Number: 657

Routine Assessment of Patient Index Data 3 Score (RAPID3) and Psoriasis Quality of Life (PQoL-12) Assess Different Domains in Psoriasis (PsO) and Psoriatic Arthritis (PsA) Patients
Abstract Number: 1417

Rural Residence Does Not Impact Total Ankle Arthroplasty Utilization and Outcomes
Abstract Number: 1375

S100A8/A9, a Serum and Imaging Biomarker for Assessing Joint Inflammation and Destruction in Experimental Seronegative Arthritis
Abstract Number: 685

Sacroiliitis Misdiagnosed As Spondyloarthritis: Clinical Analysis of 581 Cases
Abstract Number: 14L

Safety and Efficacy of ABT-494, a Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
Abstract Number: 937

Safety and Efficacy of Canakinumab in Patients with CAPS: Interim Results from the Beta-Confident Registry
Abstract Number: 13L

Safety and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis
Abstract Number: 2419

Safety and Efficacy of Etanercept in 2000 Patients with Juvenile Idiopathic Arthritis (JIA) in the JIA Biologics Register

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].